TASK DEFINITION: Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
PROBLEM: Paragraph: Authorities are hoping large-scale manufacturers can use their low-cost supply chains and digital design expertise, including 3D printing, and repurpose some factories in order to make up the expected shortfall in vital medical hardware. Some of Britain's biggest aerospace and car companies have formed three teams to produce basic ventilators to help the country's National Health Service cope with the coronavirus outbreak. Meggitt Plc, which builds components including oxygen systems for civil aerospace and military fighter programs, is leading one consortium alongside engineers GKN, Thales SA and Renishaw Plc. The other two teams are being led by carmakers McLaren, which is looking at how to design a simple version of a ventilator, and Nissan Motor Co, which is working with others to support existing ventilator producers. Ventilators, machines which move air in and out of the lungs, could be the difference between life and death for coronavirus patients suffering breathing difficulties. But getting new production up to speed will not be easy, some in the manufacturing industry said. "Precision milling and 3D printing techniques could help manufacture complex parts," said Rene-Christopher Wollmann, program and platform director at Automobili Pininfarina, which uses virtual design software to build electric hypercars. "But this depends on how much know-how existing manufacturers (of ventilators) are prepared to share about the design of such a machine," he added. "Another bottleneck will be assembling such machines under conditions which are adequate for the medical industry." The idea of using automakers to supply medical equipment got started in China, where electric car maker BYD earlier this month began turning out 5 million face masks and 300,000 bottles of hand sanitizer a day. The Shenzhen-based automaker is backed by U.S. investor Warren Buffett. Since then the idea has spread to other industries and countries. European aerospace group Airbus is working across its processes to see if its 3D printing or production facilities can be of use. "The aim is for there to be a (ventilator) prototype in two weeks and for manufacturing to start in four weeks," one person familiar with the situation at the company said. In northern Italy, the epicenter of the virus outbreak outside China, Italian carmakers Ferrari and Fiat Chrysler Automobiles NV are in talks with the nation's biggest ventilator manufacturer to help it boost production, company officials said on Thursday. The Italian government has embarked on a big expansion of intensive care beds, many of which will require ventilators. A source familiar with the matter said sports car maker Ferrari NV would be ready to start manufacturing ventilator parts in its famous Maranello headquarters, close to a ventilator factory operated by small medical equipment maker Siare Engineering. The luxury carmaker had yet to make a final decision. "We're talking to Fiat Chrysler, with Ferrari and (component maker) Marelli to try to understand if they can lend us a hand in this process for the electronics part," Siare Engineering Chief Executive Gianluca Preziosa told Reuters. Siare could also benefit from the automakers' purchasing power, Preziosa said. A spokesman for Exor NV, parent firm of both Fiat Chrysler and Ferrari, said meetings had taken place on Thursday with Siare to study the feasibility of the idea and that a decision was expected shortly. The spokesman said two main options were being considered: help Siare to engineer a capacity increase at its plant with the support of technicians provided by Fiat Chrysler and Ferrari; or outsource production of ventilator parts to the carmakers' facilities. In the United States, the federal government is in talks with Detroit auto giants General Motors Co and Ford Motor Co about how they can help expand ventilator production, the companies and White House officials said on Wednesday. It would not be the first time Detroit retooled auto plants to confront a national crisis. During World War Two Ford, GM and the former Chrysler stopped building cars and directed their factories and engineers to mass-produce airplanes, tanks and other weaponry at unprecedented levels, earning Detroit the nickname the "Arsenal of Democracy." On Wednesday, U.S. President Donald Trump said he would invoke the Defense Production Act, a law dating back to the Korean War of the 1950s which grants the president broad authority to "expedite and expand the supply of resources from the U.S. industrial base," which could allow the government to speed production of masks, respirators, ventilators and other needed equipment. Ford CEO Jim Hackett told employees in a town hall meeting that Ford is working on building ventilators if the idea is feasible. GM CEO Mary Barra spoke to White House economic adviser Larry Kudlow about the issue after the company announced it would suspend North American production through March 30. Separately, Tesla CEO Elon Musk used his Twitter account to offer his company's services. "We will make ventilators if there is a shortage," Musk tweeted, responding to a suggestion that the billionaire repurpose a factory for the task. The comment immediately drew hundreds of replies urging him to act. Claim: World's governments draft manufacturers for virus treatment arsenal.

SOLUTION: From Washington to London, Beijing to Rome, governments are drafting automakers and aerospace manufacturers to ramp up production of ventilators and other medical equipment to bolster what most experts say is an inadequate arsenal of coronavirus treatment tools.

PROBLEM: Paragraph: The lawsuit marks the first multi-plaintiff trial in the litigation over whether glyphosate, Roundup's active ingredient, is carcinogenic, and is the first trial outside of California. It is being held in St. Louis, where Monsanto was headquartered before Bayer bought the company in a $63 billion deal in 2018. Three consecutive juries found the company liable for causing cancer with damages of tens of millions of dollars awarded to each plaintiff. Bayer is appealing those verdicts. Court-appointed mediator Ken Feinberg has put the number of Roundup cancer claimants at more than 75,000 while Bayer said the claims it has been served with in court were below 50,000. Bayer's share price has tumbled since the first verdict in August 2018 but the stock rose 3% on Friday after Bloomberg reported a possible out-of-court settlement with some plaintiffs that could lead to a total payout of about $10 billion. While traders said the market likes the idea of Bayer settling the litigation, some cautioned that the prospect of a comprehensive deal remained uncertain. Analysts have estimated the size of any such settlement at $8-$12 billion. While most plaintiffs' lawyers have agreed to postpone trials pending negotiations, some have decided to pursue their clients' day in court. The case in Missouri's Circuit Court for the 22nd Judicial Circuit of the City of St. Louis is scheduled to last several weeks, with both sides presenting extensive scientific evidence through expert witnesses. Bayer denies all allegations that Roundup or glyphosate causes cancer, saying decades of independent studies have shown the world's most widely used weed killer to be safe for human use and noting that regulators around the world have approved the product. "At the end of the day, this trial should come down to the weight of the science, and we remain confident in the extensive scientific record and regulatory assessments that support the safety of our glyphosate-based herbicides and that they do not cause cancer," the company said in a statement. Several court cases have been postponed by both parties in the past to expedite settlement talks. By pursuing the St. Louis trail The Miller Firm LLC, a key player in the litigation, is seeking to increase pressure on Bayer. The case involves the claims of Bryce Batiste from Louisiana, Ann Meeks from Florida, Glen Ashelman from Pennsylvania and Christopher Wade, a St. Louis resident. All four have been diagnosed with non-Hodgkin's lymphoma, a blood cell cancer that plaintiffs in the litigation allege is caused by Roundup. Some legal experts said Bayer could benefit from a home advantage in the St. Louis trial, where Monsanto has century-old roots. But juries in the city are also known to dole out massive damages awards against large corporations. Claim: Bayer faces fourth U.S. Roundup cancer trial in Monsanto's hometown.

SOLUTION: Bayer AG is set to face a fourth U.S. jury trial over allegations that its Roundup weed killer causes cancer, with four cancer patients in the hometown of its agricultural subsidiary Monsanto scheduled to begin making their case on Friday.

PROBLEM: Paragraph: A nurse prepares a bottle of donated milk for a baby at Son Dureta's Hospital in Palma de Mallorca, Spain March 10, 2006. REUTERS/Dani Cardona The chemical bisphenol A, or BPA, is commonly used in plastic food and beverage containers and in the coating of food cans. Until now, environmental and consumer activists who have questioned the safety of BPA have relied on animal studies. But the study by British researchers in the Journal of the American Medical Association found that among 1,455 U.S. adults, those with the highest levels of BPA were more likely to have heart disease, diabetes and liver-enzyme abnormalities than those with the lowest levels. U.S. Food and Drug Administration officials said they would review the new findings, which were not yet published when the agency issued a draft conclusion in August that BPA is safe at current exposure levels. "We have confidence in the data that we've looked at and the data that we're relying on to say that the margin of safety is adequate," FDA official Laura Tarantino said at a meeting of experts advising the agency on whether it made the right call. "There are things you can do if you choose to reduce your level of bisphenol A," Tarantino said. "But we have not recommended that anyone change their habits or change their use of any of these products because right now we don't have the evidence in front of us to suggest that people need to." Panel chairman Martin Philbert declined to say what the committee's next move would be. BPA is used to make polycarbonate plastic, a clear shatter-resistant material in products ranging from baby bottles to medical devices. BPA can mimic the hormone estrogen in the body. People can consume BPA when it leaches out of the plastic into baby formula, water or food inside a container. Some retailers and manufacturers are moving away from products with BPA. Canadian officials have concluded BPA was harmful. Steven Hentges of the American Chemistry Council, an industry group, said the study's design did not allow for anyone to conclude BPA causes heart disease and diabetes. "On the other hand, though, bisphenol A has been very intensively studied in a very large number of laboratory animal studies. And the weight of evidence from those studies ... continues to support the safe use of products containing bisphenol A," he said in a telephone interview. The British researchers, who acknowledged their findings are not proof that the chemical is causing the harm, analyzed urine samples from a U.S. government health survey of adults ages 18-74 representative of the U.S. population. The 25 percent of people with the highest levels of bisphenol A in their bodies were more than twice as likely to have heart disease, including heart attacks or type 2 diabetes, compared to the 25 percent with the lowest levels. At the FDA panel meeting, several scientists and activists said the FDA ignored animal studies finding health concerns and some called for the chemical to be banned in food containers. Democratic U.S. Rep. John Dingell of Michigan, who heads the House Committee on Energy and Commerce, said the FDA has "focused myopically on industry-funded research." Iowa Republican Sen. Chuck Grassley, ranking member of the Committee on Finance, released a letter he wrote to FDA Commissioner Dr. Andrew von Eschenbach asking why the agency has not appointed a safety panel to review BPA. Tarantino said nothing was ignored but industry-funded studies finding no harm were important in the conclusions. The panel is expected to present its advice to the FDA next month. Tarantino, head of the FDA's office of food additive safety, said there is talk of government scientists doing their own BPA safety studies, but that could take years to conduct. Claim: Common plastics chemical linked to heart problems.

SOLUTION:
A major study links a chemical widely used in plastic products, including baby bottles, to health problems in humans like heart disease and diabetes, but U.S. regulators said on Tuesday they still believe it is safe.